(Q38772466)

6 September 2017

title

A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications (English)

1 reference

6 September 2017

0 references

Kyle John Wilby

2

0 references

author name string

Hazem Elewa

series ordinal

1

1 reference

6 September 2017

publication date

9 January 2017

1 reference

European Journal of Drug Metabolism and Pharmacokinetics

6 September 2017

published in

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

6 September 2017

1 reference

Pharmacokinetics of antimalarials in pregnancy: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

The origins of antimalarial-drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Spread of artemisinin resistance in Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Artemisinin-resistant malaria: research challenges, opportunities, and public health implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Genomic medicine--an updated primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Pharmacogenetics of antimalarial drugs: effect on metabolism and transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Gene, ethnic and gender influences predisposition of adverse drug reactions to artesunate among Malaysians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Single dose pharmacokinetics of proguanil and its metabolites in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

CYP2A6 genetic variation and potential consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Drug-induced haemolysis and renal failure in children with glucose-6-phosphate dehydrogenase deficiency in Afghanistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Disruption of a Plasmodium falciparum Multidrug Resistance-associated Protein (PfMRP) Alters Its Fitness and Transport of Antimalarial Drugs and Glutathione

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Drug resistance and genetic mapping in Plasmodium falciparum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Molecular analysis of pfatp6 and pfmdr1 polymorphisms and their association with in vitro sensitivity in Plasmodium falciparum isolates from the Thai-Myanmar border.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

Linkage between Deficiency of Glucose-6-phosphate Dehydrogenase and Colour-blindness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13318-016-0399-1

The activity of proguanil and its metabolites, cycloguanil and p-chlorophenylbiguanide, against Plasmodium falciparum in vitro.

21 January 2018

1 reference

12 December 2020

Pharmacogenetic application in drug development and clinical trials

1 reference

12 December 2020

CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure

1 reference

12 December 2020

Diagnosis and management of G6PD deficiency

1 reference

12 December 2020

Primaquine sensitivity in Caucasians: hemolytic reactions induced by primaquine in G-6-PD deficient subjects

1 reference

12 December 2020

Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans

1 reference

12 December 2020

Studies on the destruction of glutathione-unstable red blood cells. The influence of fava beans and primaquine upon such cells in vivo.

1 reference

12 December 2020

Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians.

1 reference

12 December 2020

10.1007/S13318-016-0399-1

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1027886009

0 references

1 reference